Get started
ABBVIE INC CEDEAR EACH 10 REPR 1 COMABBVIE INC CEDEAR EACH 10 REPR 1 COMABBVIE INC CEDEAR EACH 10 REPR 1 COM

ABBVIE INC CEDEAR EACH 10 REPR 1 COM

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Seasonals Bonds

ABBV chart


Full chart

Key facts today

BMO Capital cut its price target for AbbVie Inc. (ABBV) to $208, and Citigroup adjusted it to $215. The average target range for AbbVie now stands between $165 and $240.
Analyze the impactAnalyze the impact

Key stats


Market capitalization
‪307.93 T‬ ARS
Dividend yield (indicated)
3.22%
Price to earnings Ratio (TTM)
8.663
Basic EPS (TTM)
2,348.057 ARS
Net income (FY)
‪1.42 T‬ ARS
Revenue (FY)
‪15.99 T‬ ARS
Shares float
—
Beta (1Y)
0.27

About AbbVie Inc.


Sector
Health Technology
CEO
Robert A. Michael
Headquarters
North Chicago
Website
abbvie.com
Founded
2011
ISIN
ARBCOM4603M9
FIGI
BBG00ZL7CCS3
AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—
‪0.00‬

ABBV news



Ideas



See all ideas 

Technicals

Summarizing what the indicators are suggesting.
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

ABBV highest yielding bonds


A
ACT4176286
Allergan Funding SCS 4.85% 15-JUN-2044
Yield to maturity
6.56%
Maturity date
Jun 15, 2044
A
ACT3910526
Actavis, Inc. 4.625% 01-OCT-2042
Yield to maturity
6.54%
Maturity date
Oct 1, 2042
A
ACT4218883
Allergan Funding SCS 4.75% 15-MAR-2045
Yield to maturity
6.44%
Maturity date
Mar 15, 2045
A
ACT4218882
Allergan Funding SCS 4.55% 15-MAR-2035
Yield to maturity
5.75%
Maturity date
Mar 15, 2035
ABBV4911706
AbbVie Inc. 3.2% 21-NOV-2029
Yield to maturity
5.70%
Maturity date
Nov 21, 2029
ABBV5759196
AbbVie Inc. 5.5% 15-MAR-2064
Yield to maturity
5.51%
Maturity date
Mar 15, 2064
ABBV5759195
AbbVie Inc. 5.4% 15-MAR-2054
Yield to maturity
5.40%
Maturity date
Mar 15, 2054
ABBV5068388
AbbVie Inc. 4.625% 01-OCT-2042
Yield to maturity
5.40%
Maturity date
Oct 1, 2042
ABBV5068389
AbbVie Inc. 4.85% 15-JUN-2044
Yield to maturity
5.37%
Maturity date
Jun 15, 2044
ABBV4693583
AbbVie Inc. 4.875% 14-NOV-2048
Yield to maturity
5.37%
Maturity date
Nov 14, 2048
ABBV5759204
AbbVie Inc. 5.35% 15-MAR-2044
Yield to maturity
5.36%
Maturity date
Mar 15, 2044

Explore more bonds 

Sparks


Curated watchlists where ABBV is featured.

See all sparks